KOL洞察报告丨神经内分泌肿瘤治疗的现状与挑战10407（英）
Topic: Neuroendocrine Tumors Physician Information KOL Insights: Neuroendocrine Tumors (NET)
报告摘要
Topic: Neuroendocrine Tumors Physician Information KOL Insights: Neuroendocrine Tumors (NET)
报告信息
- 文件全名
- 《KOL洞察报告丨神经内分泌肿瘤治疗的现状与挑战10407（英）-9页.pdf》
- 适合读者
- 核心数据
- Only 20% of patients receive treatments as adjuvant therapies when patients have been diagnosed at an early stage,
- but 100% of patients who relapse locally or at distant receive therapies. Only 20% of patients who have been diagnosed
- locally receive adjuvant treatment when they have any features of poor prognosis. But 80% of patients at diagnosis
- 核心议题
常见问题
《KOL洞察报告丨神经内分泌肿瘤治疗的现状与挑战10407（英）》主要包含哪些内容?
Topic: Neuroendocrine Tumors Physician Information KOL Insights: Neuroendocrine Tumors (NET)核心数据:Only 20% of patients receive treatments as adjuvant therapies when patients have been diagnosed at an early stage,;but 100% of patients who relapse locally or at distant receive therapies. Only 20% of patients who have been diagnosed;locally receive adjuvant treatment when they have any features of poor prognosis. But 80% of patients at diagnosis。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 9。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了管理咨询等议题。
继续阅读
查看全部 →